Molecular Net Debt vs Current Deferred Revenue Analysis

MOLN Stock

USD 3.78 0.09 2.33%

Molecular Partners financial indicator trend analysis is infinitely more than just investigating Molecular Partners recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Partners is a good investment. Please check the relationship between Molecular Partners Net Debt and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Partners Net Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Molecular Partners' Net Debt and Current Deferred Revenue is 0.3. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Molecular Partners AG, assuming nothing else is changed. The correlation between historical values of Molecular Partners' Net Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Molecular Partners AG are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Debt i.e., Molecular Partners' Net Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Molecular Partners' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Molecular Partners' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 20th of May 2024, Enterprise Value Over EBITDA is likely to grow to 1.22, while Selling General Administrative is likely to drop about 12.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	548K	605K	49K	46.6K
Depreciation And Amortization	2.7M	3.5M	2.4M	2.1M

Interest Expense Depreciation And Amortization

Molecular Partners fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.55	-0.04	0.96	0.47	-0.16	-0.49	-0.38	0.15	0.47	0.45	-0.34	0.96	-0.26	0.67	0.54	-0.53	-0.47	-0.11	0.74	-0.36	0.58	1.0	-0.7	0.01	0.72
Other Current Liab	0.55		0.49	0.51	0.82	0.22	0.04	-0.93	0.76	-0.06	0.84	-0.51	0.41	0.1	0.91	0.76	-0.74	-0.6	0.41	0.93	-0.14	0.7	0.52	-0.79	0.66	0.88
Total Current Liabilities	-0.04	0.49		-0.24	0.54	0.95	0.36	-0.43	0.8	-0.21	0.55	-0.51	-0.17	0.42	0.27	0.1	0.11	0.05	0.5	0.24	0.75	-0.01	-0.07	-0.16	0.42	0.16
Total Stockholder Equity	0.96	0.51	-0.24		0.39	-0.38	-0.48	-0.35	0.02	0.47	0.37	-0.26	0.95	-0.33	0.69	0.58	-0.63	-0.51	-0.17	0.74	-0.6	0.6	0.96	-0.7	0.0	0.74
Property Plant And Equipment Net	0.47	0.82	0.54	0.39		0.29	0.16	-0.85	0.62	-0.16	1.0	-0.5	0.41	-0.17	0.81	0.79	-0.54	-0.5	0.21	0.81	0.03	0.75	0.42	-0.42	0.48	0.81
Current Deferred Revenue	-0.16	0.22	0.95	-0.38	0.29		0.3	-0.13	0.63	-0.11	0.29	-0.44	-0.26	0.42	0.0	-0.2	0.37	0.32	0.37	-0.04	0.86	-0.3	-0.18	0.0	0.23	-0.13
Net Debt	-0.49	0.04	0.36	-0.48	0.16	0.3		-0.06	0.39	-0.86	0.18	-0.26	-0.57	0.44	-0.14	0.11	0.2	-0.08	0.49	-0.14	0.29	-0.1	-0.51	0.37	0.36	-0.1
Retained Earnings	-0.38	-0.93	-0.43	-0.35	-0.85	-0.13	-0.06		-0.67	0.19	-0.87	0.32	-0.25	-0.06	-0.87	-0.82	0.75	0.69	-0.41	-0.87	0.14	-0.82	-0.34	0.58	-0.65	-0.86
Accounts Payable	0.15	0.76	0.8	0.02	0.62	0.63	0.39	-0.67		-0.29	0.64	-0.38	-0.01	0.4	0.51	0.39	-0.2	-0.28	0.74	0.54	0.4	0.28	0.12	-0.47	0.57	0.44
Cash	0.47	-0.06	-0.21	0.47	-0.16	-0.11	-0.86	0.19	-0.29		-0.19	0.13	0.57	-0.4	0.17	-0.17	-0.02	0.26	-0.45	0.12	-0.21	-0.11	0.49	-0.37	-0.4	0.08
Non Current Assets Total	0.45	0.84	0.55	0.37	1.0	0.29	0.18	-0.87	0.64	-0.19		-0.53	0.38	-0.14	0.82	0.78	-0.55	-0.5	0.22	0.81	0.03	0.74	0.41	-0.44	0.54	0.82
Non Currrent Assets Other	-0.34	-0.51	-0.51	-0.26	-0.5	-0.44	-0.26	0.32	-0.38	0.13	-0.53		-0.29	-0.02	-0.42	-0.26	0.23	-0.02	0.11	-0.4	-0.15	-0.06	-0.32	0.44	-0.55	-0.37
Cash And Short Term Investments	0.96	0.41	-0.17	0.95	0.41	-0.26	-0.57	-0.25	-0.01	0.57	0.38	-0.29		-0.5	0.59	0.44	-0.47	-0.3	-0.33	0.64	-0.42	0.5	0.96	-0.64	-0.1	0.63
Net Receivables	-0.26	0.1	0.42	-0.33	-0.17	0.42	0.44	-0.06	0.4	-0.4	-0.14	-0.02	-0.5		-0.11	-0.04	0.18	-0.27	0.77	-0.09	0.39	-0.15	-0.25	0.1	0.19	-0.12
Common Stock Total Equity	0.67	0.91	0.27	0.69	0.81	0.0	-0.14	-0.87	0.51	0.17	0.82	-0.42	0.59	-0.11		0.86	-0.79	-0.65	0.19	0.98	-0.36	0.79	0.64	-0.73	0.47	0.98
Common Stock Shares Outstanding	0.54	0.76	0.1	0.58	0.79	-0.2	0.11	-0.82	0.39	-0.17	0.78	-0.26	0.44	-0.04	0.86		-0.71	-0.86	0.28	0.87	-0.4	0.92	0.51	-0.41	0.38	0.93
Non Current Liabilities Total	-0.53	-0.74	0.11	-0.63	-0.54	0.37	0.2	0.75	-0.2	-0.02	-0.55	0.23	-0.47	0.18	-0.79	-0.71		0.67	-0.06	-0.82	0.69	-0.77	-0.51	0.68	-0.44	-0.83
Inventory	-0.47	-0.6	0.05	-0.51	-0.5	0.32	-0.08	0.69	-0.28	0.26	-0.5	-0.02	-0.3	-0.27	-0.65	-0.86	0.67		-0.48	-0.71	0.42	-0.88	-0.45	0.31	-0.27	-0.76
Other Current Assets	-0.11	0.41	0.5	-0.17	0.21	0.37	0.49	-0.41	0.74	-0.45	0.22	0.11	-0.33	0.77	0.19	0.28	-0.06	-0.48		0.24	0.29	0.2	-0.12	-0.08	0.23	0.18
Other Stockholder Equity	0.74	0.93	0.24	0.74	0.81	-0.04	-0.14	-0.87	0.54	0.12	0.81	-0.4	0.64	-0.09	0.98	0.87	-0.82	-0.71	0.24		-0.38	0.83	0.71	-0.77	0.46	0.99
Total Liab	-0.36	-0.14	0.75	-0.6	0.03	0.86	0.29	0.14	0.4	-0.21	0.03	-0.15	-0.42	0.39	-0.36	-0.4	0.69	0.42	0.29	-0.38		-0.43	-0.37	0.34	0.02	-0.44
Property Plant And Equipment Gross	0.58	0.7	-0.01	0.6	0.75	-0.3	-0.1	-0.82	0.28	-0.11	0.74	-0.06	0.5	-0.15	0.79	0.92	-0.77	-0.88	0.2	0.83	-0.43		0.55	-0.41	0.31	0.88
Total Current Assets	1.0	0.52	-0.07	0.96	0.42	-0.18	-0.51	-0.34	0.12	0.49	0.41	-0.32	0.96	-0.25	0.64	0.51	-0.51	-0.45	-0.12	0.71	-0.37	0.55		-0.69	-0.02	0.69
Short Term Debt	-0.7	-0.79	-0.16	-0.7	-0.42	0.0	0.37	0.58	-0.47	-0.37	-0.44	0.44	-0.64	0.1	-0.73	-0.41	0.68	0.31	-0.08	-0.77	0.34	-0.41	-0.69		-0.47	-0.68
Intangible Assets	0.01	0.66	0.42	0.0	0.48	0.23	0.36	-0.65	0.57	-0.4	0.54	-0.55	-0.1	0.19	0.47	0.38	-0.44	-0.27	0.23	0.46	0.02	0.31	-0.02	-0.47		0.44
Common Stock	0.72	0.88	0.16	0.74	0.81	-0.13	-0.1	-0.86	0.44	0.08	0.82	-0.37	0.63	-0.12	0.98	0.93	-0.83	-0.76	0.18	0.99	-0.44	0.88	0.69	-0.68	0.44

Click cells to compare fundamentals

Molecular Partners Account Relationship Matchups

Molecular Partners fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Other Current Liab	7.0M	10.7M	12.5M	8.6M	8.5M	6.9M
Total Current Liabilities	28.6M	57.7M	46.9M	17.3M	14.4M	13.7M
Total Stockholder Equity	54.1M	107.2M	107.3M	235.2M	176.4M	137.3M
Property Plant And Equipment Net	4.2M	9.4M	8.1M	7.2M	5.7M	4.7M
Current Deferred Revenue	18.3M	42.9M	28.3M	6.4M	4.3M	4.1M
Net Debt	(73.2M)	(126.5M)	(65.8M)	(83.1M)	(183.2M)	(192.4M)
Retained Earnings	(130.9M)	(195.2M)	(251.0M)	(127.8M)	(191.8M)	(182.2M)
Accounts Payable	2.0M	2.8M	4.9M	997K	410K	389.5K
Cash	75.7M	133.7M	71.8M	87.9M	186.9M	103.0M
Non Current Assets Total	5.0M	9.7M	8.5M	7.5M	5.9M	5.0M
Cash And Short Term Investments	95.1M	173.7M	132.8M	249.1M	186.9M	175.8M
Net Receivables	2.5M	2.8M	25.7M	1.7M	1.7M	1.7M
Common Stock Total Equity	2.1M	2.1M	2.2M	2.9M	3.4M	2.3M
Common Stock Shares Outstanding	21.4M	25.0M	31.0M	33.3M	32.8M	26.0M
Liabilities And Stockholders Equity	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Non Current Liabilities Total	22.2M	22.7M	18.5M	9.8M	7.5M	7.1M
Inventory	(51.6M)	(486K)	(199K)	(86.7M)	(78.1M)	(74.2M)
Other Current Assets	2.8M	1.5M	92.4M	3.9M	3.8M	3.6M
Other Stockholder Equity	182.8M	299.5M	355.0M	360.3M	364.5M	250.9M
Total Liab	50.8M	80.3M	65.4M	27.1M	21.9M	40.7M
Property Plant And Equipment Gross	4.2M	9.4M	20.9M	21.9M	22.0M	23.1M
Total Current Assets	99.9M	177.8M	164.2M	254.8M	192.5M	188.3M
Intangible Assets	772K	347K	330K	271K	212K	245.5K
Common Stock	2.2M	2.9M	3.2M	3.6M	3.6M	2.7M
Short Term Investments	19.4M	40M	61M	161.2M	119.6M	125.6M
Other Liab	20.9M	16.6M	13.7M	6.2M	5.6M	5.3M
Net Tangible Assets	53.4M	106.9M	107.0M	234.9M	270.1M	283.6M
Net Invested Capital	54.1M	107.2M	107.3M	235.2M	176.4M	139.6M
Net Working Capital	71.3M	120.1M	117.3M	237.5M	178.0M	152.3M
Property Plant Equipment	4.2M	9.4M	8.1M	7.2M	8.3M	5.9M
Capital Stock	2.2M	2.9M	3.2M	3.6M	3.6M	3.2M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:

How To Invest In Molecular

Details

Is Molecular Stock a good investment?

Details

What is Molecular Partners' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Molecular Stock analysis

When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.

	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

0.215

Quarterly Revenue Growth

(0.62)

Return On Assets

(0.17)

Return On Equity

(0.30)

The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Molecular Net Debt vs Current Deferred Revenue Analysis

Net Debt vs Current Deferred Revenue

Net Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Net Debt

Current Deferred Revenue

Molecular Partners fundamental ratios Correlations

Molecular Partners Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Molecular Partners fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Molecular Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 0.99	Other Stockholder Equity
Other Stockholder Equity	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Common Stock Total Equity
Total Stockholder Equity	+ 0.96	Total Assets

Retained Earnings	- 0.93	Other Current Liab
Property Plant And Equipment Gross	- 0.88	Inventory
Other Stockholder Equity	- 0.87	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Non Current Assets Total	- 0.87	Retained Earnings
Inventory	- 0.86	Common Stock Shares Outstanding